Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

REGN Regeneron Pharmaceuticals Inc
$776.60 0.00% 0.00
Notify me if price changes either direction
Interactive Brokers Logotype

Buy REGN stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 82.0B
Enterprise value 72.4B
Trailing PE 18.315348
Forward PE 14.454193
PEG Ratio -4.88218495125
Enterprise to EBITDA 17.049
Enterprise to revenue 5.047
Price to book MRQ 2.4955688
Price to sales TTM 5.60386

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 14.3B
EBITDA 5.0B
Diluted EPS TTM 41.51
Total Cash (MRQ) 8.6B
Current ratio (MRQ) 4.126
Operating Cash Flow (TTM) 5.0B

REGN trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent REGN News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.